Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Increases By 137.6%

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) saw a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 11,951 shares, a growth of 137.6% from the February 12th total of 5,030 shares. Based on an average daily trading volume, of 1,671 shares, the short-interest ratio is presently 7.2 days. Approximately 1.1% of the company’s stock are sold short. Approximately 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 1,671 shares, the short-interest ratio is presently 7.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Friday, January 9th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Addex Therapeutics Stock Performance

ADXN stock opened at $7.26 on Friday. The company’s 50 day moving average price is $7.64 and its 200 day moving average price is $8.28. Addex Therapeutics has a fifty-two week low of $6.51 and a fifty-two week high of $12.05. The firm has a market capitalization of $8.93 million, a price-to-earnings ratio of -1.26 and a beta of 1.46.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.